Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Infectious Diseases

• Publication date

  2013-05-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/cit334PMID 23697744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

  2013influential reference
• Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill

  2012influential reference
• Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.

  2012cited by this paper
• Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.

  2012influential reference
• Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design

  2012cited by this paper
• Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

  2011influential reference
• Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.

  2011cited by this paper
• Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models

  2011cited by this paper
• Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT

  2011cited by this paper
• fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

  2010cited by this paper
• The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic.

  2010cited by this paper
• Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

  2009influential reference
• Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models

  2009cited by this paper
• NONMEM User’s Guides. (1989–2009)

  2009cited by this paper
• Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

  2008influential reference
• Pharmacokinetics of intravenous polymyxin B in critically ill patients.

  2008cited by this paper
• Polymyxins Revisited

  2008cited by this paper
• Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.

  2007cited by this paper
• Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa

  2006influential reference
• Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

  2006cited by this paper
• Quantification of Lean Bodyweight

  2005cited by this paper
• Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

  2005cited by this paper
• Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration

  2003influential reference
• On the meaning of the intact nephron hypothesis.

  1969cited by this paper

• A Multi-Center Study of Population Pharmacokinetics of Polymyxin B in Critically Ill Patients

  2026influential citation
• Evaluation of polymyxin B-associated acute kidney injury in carbapenem-resistant infections: A systematic review and meta-analysis

  2026cites this paper
• Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care.

  2026cites this paper
• Pharmacokinetics of polymyxin b loading dose in patients with sepsis caused by polyresistant gram-negative microorganisms

  2026cites this paper
• Pharmacodynamic Insights to Support Pneumonia Treatment in a Patient Co-Infected with Two Carbapenem-Resistant Bacteria.

  2025cites this paper
• In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii

  2025cites this paper
• In Vitro Neurotoxicity Comparison: Colistimethate Induces Higher Toxicity Than Colistin via Formaldehyde Accumulation.

  2025cites this paper
• Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

  2025cites this paper
• An external validation of the population pharmacokinetic models of polymyxin B in critically ill patients

  2025cites this paper
• Tailor-Engineered nano-diagnostic platform for polymyxin B monitoring and its biological application based on molecularly imprinted Sulphur-doping graphene quantum dot–derived

  2025cites this paper
• Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations

  2025cites this paper
• Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis

  2025cites this paper
• Pharmacodynamics of aztreonam/ceftazidime/avibactam and polymyxin B versus New Delhi MBL-producing Acinetobacter baumannii

  2025cites this paper
• Polymyxin B in The Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacteria in Children: A Retrospective Case Series and A Literature Review

  2025cites this paper
• Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producing Klebsiella pneumoniae persisters

  2025cites this paper
• Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter Baumannii

  2025cites this paper
• Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria

  2025influential citation
• Multidrug-resistant Gram-negative Organisms: A Primer on Mechanisms of Resistance and Emerging Therapies for the non-Infectious Diseases Clinician.

  2025cites this paper
• A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations

  2025influential citation
• Effects of In Vitro Combination Therapy with Polymyxin B on Delaying Resistance in Klebsiella pneumoniae and Insights into the Mechanisms of Polymyxin-Induced Resistance.

  2025cites this paper
• Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia

  2025cites this paper
• Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentration

  2025cites this paper
• Noncytotoxic polymyxin derivatives enhance antibiotic action against multidrug-resistant Gram-negative bacteria

  2025cites this paper
• Polymyxines

  2025cites this paper
• An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae.

  2025cites this paper
• Effect of Renal Filtration Function on Polymyxin B Pharmacokinetics in Patients with Sepsis

  2025cites this paper
• Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of Gram-negative bacteremia

  2025cites this paper
• An antimicrobial peptide as a potential therapy for bacterial pneumonia that alleviates antimicrobial resistance

  2025cites this paper
• A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction

  2024cites this paper
• Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China

  2024cites this paper
• Activity of polymyxin B combined with cefepime-avibactam against the biofilms of polymyxin B-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae in in vitro and in vivo models

  2024cites this paper
• Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency

  2024cites this paper
• Pharmacokinetics of polymyxin B in different populations: a systematic review

  2024cites this paper
• Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling

  2024cites this paper
• Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?

  2024cites this paper
• The in vitro Activity of Omadacycline Alone and in Combination Against Carbapenem-Resistant Klebsiella pneumoniae

  2024cites this paper
• Transcriptomic analysis of induced resistance to polymyxin in carbapenem-resistant Enterobacter cloacae complex isolate carrying mcr-9.

  2024cites this paper
• How can polymyxin B be dosed based on current pharmacokinetic knowledge?

  2024cites this paper
• A simple HPLC–MS/MS method for the determination of polymyxin B in human plasma and its application in the pharmacokinetic study in elderly patients infected with multidrug-resistant Gram-negative bacteria

  2024cites this paper
• Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae

  2024cites this paper
• PBP-3 Directed Therapy in VIM-producing Pseudomonas aeruginosa Creates Bacterial Transformers, Persisters in Disguise.

  2024cites this paper
• Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects.

  2024cites this paper
• Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis

  2024cites this paper
• Cost-effectiveness analysis of polymyxin B versus colistin for treating patients with carbapenem-resistant gram-negative bacterial infections

  2024cites this paper
• Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

  2024cites this paper
• Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models

  2024cites this paper
• Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis.

  2024cites this paper
• Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections

  2024cites this paper
• Model-Based Learn and Confirm: Designing Effective Treatment Regimens Against Multidrug Resistant Gram-negative Pathogens.

  2024cites this paper
• Impact of nutritional factors on the in vitro PK/PD modelling of polymyxin B against various strains of Acinetobacter baumannii.

  2024cites this paper
• Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation

  2024cites this paper
• Optimization of an in vitro Pseudomonas aeruginosa Biofilm Model to Examine Antibiotic Pharmacodynamics at the Air-Liquid Interface

  2024cites this paper
• Guidelines for Antibiotics Prescription in Critically Ill Patients

  2024cites this paper
• Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections

  2023cites this paper
• Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

  2023cites this paper
• Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex

  2023cites this paper
• Model-Informed Dose Optimisation of Polymyxin-Rifampicin Combination Therapy against Multidrug-Resistant Acinetobacter baumannii.

  2023cites this paper
• Quality analysis of prescriptions of polymyxin B in a high-complexity public hospital

  2023cites this paper
• Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial

  2023influential citation
• Population pharmacokinetics of polymyxin B in patients with liver dysfunction

  2023cites this paper
• A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalised patients.

  2023cites this paper
• Polysaccharide-Targeting Lipid Nanoparticles to Kill Gram-Negative Bacteria.

  2023cites this paper
• Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients

  2023cites this paper
• Current State of Antimicrobial Treatment of Lower Respiratory Tract Infections Due to Carbapenem-Resistant Acinetobacter baumannii

  2023cites this paper
• Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice

  2023cites this paper
• Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study

  2023cites this paper
• Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society

  2023cites this paper
• Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models

  2023cites this paper
• Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.

  2023cites this paper
• Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae

  2023cites this paper
• Comprehensive guidance for antibiotic dosing in obese adults: 2022 update

  2023cites this paper
• Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?

  2023cites this paper
• Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients

  2023cites this paper
• Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria

  2023cites this paper
• Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions

  2023cites this paper
• Therapeutic Drug monitoring of colistin in critically ill patients: A narrative review

  2023cites this paper
• Polymyxin B in Patients With Renal Impairment: Is It Necessary to Adjust Dose?

  2022cites this paper
• Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity

  2022cites this paper
• Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.

  2022cites this paper
• Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function.

  2022cites this paper
• Unbound serum polymyxin B in patients with sepsis: Detection approaches and limited sampling strategy for clinical practice and research.

  2022cites this paper
• The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation

  2022influential citation
• Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

  2022cites this paper
• Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients

  2022cites this paper
• Population Pharmacokinetics of Polymyxin B and Dosage Strategy in Critically Ill Patients With/without Continuous Renal Replacement Therapy.

  2022cites this paper
• Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients

  2022cites this paper
• Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility

  2022cites this paper
• Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy

  2022cites this paper
• Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

  2022influential citation
• A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug‐resistant gram‐negative bacteria

  2022influential citation
• Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety

  2022cites this paper
• Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance

  2022cites this paper
• Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment

  2022cites this paper
• Population pharmacokinetics of polymyxin B: a systematic review

  2022influential citation
• Application of the Adverse Outcome Pathway Concept to In Vitro Nephrotoxicity Assessment: Kidney Injury due to Receptor-Mediated Endocytosis and Lysosomal Overload as a Case Study

  2022cites this paper
• Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae.

  2022cites this paper
• Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens

  2022cites this paper
• Determination of polymyxin B in dried blood spots using LC-MS/MS for therapeutic drug monitoring.

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of peptide antibiotics.

  2022cites this paper
• Polymyxin Induces Significant Transcriptomic Perturbations of Cellular Signalling Networks in Human Lung Epithelial Cells

  2022cites this paper